Biologics Contract Development Market Size, Share & Trends Analysis Report By Source (Mammalian, Microbial), By Service Type, By Indication (Oncology, Immunological Disorders), By Region And Segment Forecasts, 2023 - 2030

Biologics Contract Development Market Growth & Trends


The global biologics contract development market size is expected to reach USD 13.8 billion by 2030, expanding at 8.1% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Key drivers attributed to the growth include rising adoption of advanced technologies by biologics manufacturers, M&A, and clinical trials in developing nations.The market includes organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in several important applications, including drug screening, gene functional studies, and biologic production.

Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth allowing more financial stability and amalgamation of advanced & specialized technologies. For instance, in September 2022, Lonza., collaborated with biotechnology company Touchlight to expand its product portfolio with different sources of DNA for developing mRNA. Touchlight entered into this partnership to expand its consumer base to the novel doggybone DNA (dbDNA) technology via Lonza's offerings.

Many biopharma and Pharma companies are increasingly looking to outsource their activities as it helps accelerate the workflow (speed) of the company, provide unique specialized services, decrease drug development costs, and provide expertise. These factors are expected to boost the biologics contract development industry's growth.

During the COVID-19 pandemic, most clinical trials were focused on developing new therapies for treating COVID-19. However, in the post-pandemic period, research is expected to focus on cancer owing to rising incidences. Biologics such as monoclonal antibodies have gained significant popularity in treating cancer. The high potential of biologics in treating cancer and the growing number of cancer studies are likely to support the growth of the market in the coming years.

Biologics Contract Development Market Report Highlights
  • Mammalian source emerged as the largest product segment in 2022 with over 52.0% share, as the majority of research is being carried out using mammalian cell lines
  • Process development is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource the production of recombinant proteins and monoclonal antibodies (MABs)
  • North America dominated the global market in 2019. An increase in strategic acquisitions & partnerships and a rise in demand for specialized testing services are likely to have a positive impact
  • Asia Pacific is expected to register the highest CAGR over the forecast period, owing to various amendments made by regulatory organizations to change clinical trials evaluation standards in tandem with global requirements and rising investment in the Asia Pacific region"


Chapter 1 Methodology And Scope
1.1 Market Segmentation & Scope
1.1.1 Source Type
1.1.2 Service Type
1.1.3 Disease Indication Type
1.1.4 Regional Scope
1.1.5 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region-Wise Market Calculation
1.6.1 Region-Wise Market: Base Estimates
1.6.2 Global Market: Cagr Calculation
1.7 Model Details
1.7.1 Commodity Flow Analysis (Model 1)
1.7.2 Volume Price Analysis (Model 2)
1.7.2.1 Service Segment Analysis
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 List Of Secondary Sources
1.11 Objectives
1.11.1 Objective - 1:
1.11.2 Objective - 2:
1.11.3 Objective - 3:
1.11.4 Objective - 4:
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Biologics Contract Development Market: Variables, Trends, & Scope
3.1 Market Segmentation And Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Increasing Adoption Of Advanced Technologies
3.2.3 Increasing Mergers And Collaborations
3.2.4 Favorable Environment For Clinical Trials In Developing Countries
3.2.5 Increasing Outsourcing Of R&D Activities
3.2.6 Market Restraint Analysis
3.2.7 Intellectual Property Rights Issues
3.3 Penetration & Growth Prospect Mapping
3.4 Biologics Contract Development: Market Analysis Tools
3.4.1 Industry Analysis - Porter’s Five Forces
3.4.2 Pestel Analysis
3.5 COVID-19 Impact On The Biologics Contract Development Market
Chapter 4 Biologics Contract Development Market: Source Type Segment Analysis
4.1 Biologics Contract Development Market: Market Share Analysis, 2022 & 2030
4.1.1 Microbial
4.1.1.1 Microbial Market, 2018 - 2030 (USD Million)
4.1.1.2 Mammalian
4.1.1.2.1 Mammalian Market, 2018 - 2030 (USD Million)
4.1.1.3 Others
4.1.1.3.1 Others Market, 2018 - 2030 (USD Million)
Chapter 5 Biologics Contract Development Market: Service Segment Analysis
5.1 Biologics Contract Development Market: Market Share Analysis, 2022 & 2030
5.2 Cell Line Development
5.2.1 Cell Line Development Market, 2018 - 2030 (USD Million)
5.2.1.1 Microbial Cell Line Development
5.2.1.1.1 Microbial Cell Line Development Market, 2018 - 2030 (USD Million)
5.2.1.2 Mammalian Cell Line Development
5.2.1.2.1 Mammalian Cell Line Development Market, 2018 - 2030 (USD Million)
5.2.1.3 Others
5.2.1.3.1 Others Market, 2018 - 2030 (USD Million)
5.2.2 Process Development
5.2.2.1 Process Development market, 2018 - 2030 (USD Million)
5.2.2.2 Upstream Process Development
5.2.2.1.1 Upstream Process Development Market, 2018 - 2030 (USD Million)
5.2.2.1.1.1 Microbial
5.2.2.1.1.1.1 Microbial Market, 2018 - 2030 (USD Million)
5.2.2.1.2.1 Mammalian
5.2.2.1.2.1.1 Mammalian Market, 2018 - 2030 (USD Million)
5.2.2.1.3.1 Others
5.2.2.1.3.1.1 Others Market, 2018 - 2030 (USD Million)
5.2.3 Downstream Process Development
5.2.3.1 Downstream Process Development, 2018 - 2030 (USD Million)
5.2.3.1.1 Impurity, Isolation, & Identification
5.2.3.1.1.1 Impurity, Isolation, & Identification Market, 2018 - 2030 (USD Million)
5.2.3.1.2 Physicochemical Characterization
5.2.3.1.2.1 Physicochemical Characterization Market, 2018 - 2030 (USD Million)
5.2.3.1.3 Pharmaceutical Analysis
5.2.3.1.3.1 Pharmaceutical Analysis Market, 2018 - 2030 (USD Million)
5.2.3.1.4 Others
5.2.3.1.4.1 Others Market, 2018 - 2030 (USD Million)
5.3.4 Downstream Process, By Product
5.3.4.1 Mabs (Monoclonal Antibodies)
5.3.4.1.1 Mabs (Monoclonal Antibodies) Market, 2018 - 2030 (USD Million)
5.3.4.2. Recombinant Proteins
5.3.4.2.1 Recombinant Proteins Analysis Market, 2018 - 2030 (USD Million)
5.3.4.3 Others
5.3.4.3.1 Others Market, 2018 - 2030 (USD Million)
5.3 Other Services (Quality And Regulatory Services, Etc)
5.3.1 Others Market, 2018 - 2030 (USD Million)
Chapter 6 Biologics Contract Development Market: Indication Segment Analysis
6.1 Biologics Contract Development Market: Market Share Analysis, 2022 & 2030
6.2 Oncology
6.2.1 Oncology Market, 2018 - 2030 (USD Million)
6.3 Immunological Disorders
6.3.1 Immunological Disorders Market, 2018 - 2030 (USD Million)
6.4 Cardiovascular Disorders
6.4.1 Cardiovascular Disorders Market, 2018 - 2030 (USD Million)
6.5 Hematological Disorders
6.5.1 Hematological Disorders Market, 2018 - 2030 (USD Million)
6.6 Others
6.6.1 others Market, 2018 - 2030 (USD Million)
Chapter 7 Biologics Contract Development Market: Regional Analysis
7.1 Biologics Contract Development: Regional Market Share Analysis, 2022 & 2030
7.2 North America
7.2.1 North America Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.2 UK
7.3.2.1 UK Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.4 France
7.3.4.1 France Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.5 Italy
7.3.5.1 Italy Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.6 Spain
7.3.6.1 Spain Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.2 China
7.4.2.1 China Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.3 India
7.4.3.1 India Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.4 Japan
7.4.4.1 Japan Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.5 Australia
7.4.5.1 Australia Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.5 Colombia
7.5.5.1 Colombia Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6.4 UAE
7.6.4.1 UAE Biologics Contract Development Market, 2018 - 2030 (USD Million)
Chapter 8 Company Profiles
8.1 Competitive Landscape
8.2 Company Profile
8.2.1 Wuxi Biologics
8.2.1.1 Company Overview
8.2.1.2 Financial Performance
8.2.1.3 Service Benchmarking
8.2.1.4 Strategic Initiatives
8.2.2 Abzena Ltd
8.2.2.1 Company Overview
8.2.2.2 Service Benchmarking
8.2.2.3 Strategic Initiatives:
8.2.3 Fujifilm Diosynth Biotechnologies
8.2.3.1 Company Overview
8.2.3.2 Financial Performance
8.2.3.3 Service Benchmarking
8.2.3.4 Strategic Initiatives
8.2.4 Kbi Biopharma
8.2.4.1 Company Overview
8.2.4.2 Service Benchmarking
8.2.4.3 Strategic Initiatives
8.2.5 Agc Biologics
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Service Benchmarking
8.2.5.4 Strategic Initiatives:
8.2.6 Thermo Fischer Scientific Inc.
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Service Benchmarking
8.2.6.4 Strategic Initiatives:
8.2.7 Curia Global, Inc
8.2.7.1 Company Overview
8.2.7.2 Service Benchmarking
8.2.7.3 Strategic Initiatives:
8.2.8 Genscript
8.2.8.1 Company Overview
8.2.8.2 Financial Performance
8.2.8.3 Service Benchmarking
8.2.8.4 Strategic Initiatives
8.2.9 Bionova Scientific Inc.
8.2.9.1 Company Overview
8.2.9.2 Service Benchmarking
8.2.10 Bioxcellence (Boehringer Ingelheim Biopharmaceuticals Gmbh)
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Service Benchmarking
8.2.10.4 Strategic Initiatives:
8.2.11 Stc Biologics
8.2.11.1 Company Overview
8.2.11.2 Service Benchmarking

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings